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Abstract Protein kinase CK2 is a pleiotropic Ser/Thr kinase
occurring as K2L2, KP2L2, or KKPL2 tetramers. A requirement in
serum-stimulated cell cycle entry in both the cytoplasm and the
nucleus of human fibroblasts for phosphorylation(s) by CK2 has
been concluded from stimulation inhibition by microinjected
antibodies against the regulatory subunit (L). We have now
examined this idea more directly by microinjection-mediated
perturbation of phosphorylation and non-phosphorylation inter-
actions of the catalytic subunits (K and KP), and by verifying the
supposed matching of the cellular partition of CK2 subunits in
the fibroblasts employed. While immunostaining and cell
fractionation indicate that the partitions of subunits indeed
match each other (with their predominant location in the nucleus
in both quiescent and serum-stimulated cells), microinjection of
substrate or pseudosubstrate peptides competing for the CK2-
mediated phosphorylation in vitro resulted in significant inhibi-
tion of serum stimulation when placed into the nucleus but not
when placed into the cytoplasm. Also inhibitory were nuclear but
not cytoplasmic injections of antibodies against K and KP that
affect neither their kinase activity in vitro nor their complexing
to L. The data indicate that the role played by CK2 in serum-
stimulated cell cycle entry is predominantly nuclear and more
complex than previously assumed, involving not only phospho-
rylation but also experimentally separable non-phosphorylation
interactions by the catalytic subunits.
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1. Introduction
Protein kinase CK2 (also known as casein kinase II) is a
pleiotropic, ubiquitous Ser/Thr kinase vital for eukaryotes.
CK2 phosphorylates at sites typically located within acidic
stretches of proteins with -Ser/Thr-X-X-Glu/Asp- as a consen-
sus. Glu/Asp are replaceable by phospho-Ser or phospho-Tyr,
a property perfectly suited for speci¢c cross-talks to other
kinases and thus for the participation of CK2 in regulatory
cellular networks. Of the many proteins phosphorylated by
CK2, a majority are involved in cell cycle-related signaling
and gene expression. CK2 of all eukaryotes investigated so
far has a tetrameric structure composed of two catalytic (K)
and two regulatory (L) subunits. Humans (and other mamma-
lians) possess an additional catalytic KP subunit, so that K2L2,
KKPL2 and KP2L2 holoenzymes are found throughout tissues in
which KL or KPL dimers are complexed via L-L interaction [1^
4]. Like the quaternary structure of CK2, the primary struc-
ture of each of the individual subunits is highly conserved, the
conservation manifested even in the structure of the genes [5^
7]. The role played by CK2 and the regulation of CK2 in cells
remain unclear. No distinct factor(s) are known to which CK2
would respond in a turn-on/o¡ manner; activity seems rather
to relate to the presence of polybasic and polyacidic molecules
as exempli¢ed by polyamines and heparin, respectively, and to
the ionic microenvironment. Subunit L seems to determine the
protein spectrum phosphorylated by CK2, and also to what
degree the phosphorylations occur [2^4]. Further, there are
indications that CK2-mediated e¡ects other than by phos-
phorylation might happen, and that ‘free’ subunits, i.e. sub-
units not complexed into CK2 holoenzymes, might be present
in cells [4]. Deviations from the tetrameric stoichiometry be-
yond certain extents have been suspected to be responsible for
a potentiation of fatal pathological situations such as theiler-
iosis or cancer [8^11].
Using perturbation assays, we had investigated CK2 for an
involvement in proliferation stimulation of human ¢broblasts
by serum, a process highly signi¢cant for wound healing [12],
and a model for cell cycle re-entry and progression [13]. Per-
turbation was achieved at the nucleic acid level with antisense
oligodeoxynucleotides directed against K and KP, or L [14],
and at the protein level with microinjected antibodies. Anti-
bodies speci¢c for L were injected into either the cytoplasm or
the nucleus of quiescent cells (serum-deprived cells, i.e. G0
phase cells) prior to stimulation by serum. As a result, stim-
ulation was signi¢cantly a¡ected and in a time- and cell com-
partment-speci¢c manner; injections into cytoplasm inhibited
stimulation when carried out during G0 to G1 phase transi-
tion, or late in the G1 phase, shortly before reaching S phase.
Injections into the nucleus led to a dramatic inhibition when
carried out during G0 to G1 phase transition and the imme-
diately adjacent part of the G1 phase [15,16]. Viewing L as a
constitutive, phosphorylation-determining part of the tetra-
meric holoenzyme, these e¡ects had been interpreted as indi-
cative for a role of CK2 holoenzymes and, consequently, for
CK2-mediated phosphorylations in serum-stimulated cell
cycle entry. However, experimental proof for this interpreta-
tion has not been provided, mainly because of a lack of ap-
propriate experimental tools at the time of investigation. In
the meantime, substrate-related peptides for CK2 have be-
come available [17], and we have successfully raised and af-
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¢nity puri¢ed a series of antibodies also against various epi-
topes of K and KP subunits [18,19].
We report here on the microinjection of a CK2 substrate
peptide and its pseudosubstrate version (Ser exchanged for
Ala) into primary human lung ¢broblasts (IMR-90 cells) to
compete for CK2-related phosphorylation reactions which
should, if the predicted involvement in cell cycle entry oc-
curred, a¡ect the serum stimulation of cells. In order to dis-
sect the kinase function from possible interactions of the cat-
alytic subunits other than by phosphorylation (non-
phosphorylation interactions), and to distinguish further be-
tween roles of K and KP in this context, we also carried out
injections of antibodies that speci¢cally recognize sequences
located downstream or upstream of the catalytic domain
areas. Occupation of the sequences by antibodies does not
interfere with the complexation of K and KP to L and has,
consequently, no e¡ect on tetramer formation and on kinase
activity [18]. The results obtained con¢rm a role of CK2 in
serum-stimulated cell cycle entry, in which the catalytic sub-
units appear to be involved not only via phosphorylation(s)
but, interestingly, also via non-phosphorylation interactions
experimentally separable from the kinase function, and in
which compartmentation seems to be of importance.
2. Materials and methods
2.1. Cell culture, synchronization, and stimulation to and monitoring of
cell cycle re-entry
Human lung primary diploid ¢broblasts (IMR-90) were obtained
from American Type Culture Collection (Rockville, MD, USA) as
passage number 8. The cells were grown on coverslips to approxi-
mately 80% con£uence in Dulbecco’s modi¢ed Eagle’s medium
(DMEM; Gibco) supplemented with 10% fetal calf serum (FCS; Gib-
co), at 37‡C, in a 5% CO2 atmosphere. Only cells with passage num-
bers less than 15 were used. The cells were arrested in the G0 phase of
the cell cycle, i.e. rendered quiescent, by withdrawing FCS from the
medium for a period of 3^5 days. Stimulation to re-enter and progress
through the cell cycle was done by replacing the medium with 20%
FCS in DMEM. The reaching of S phase was monitored by the
incorporation of 5-bromo-2P-deoxyuridine (BrdU; Sigma) into DNA
using indirect immuno£uorescence microscopy. The procedure has
been extensively characterized [15,16].
2.2. Peptides, antibodies, and recombinant proteins
Peptides representing the CK2 model substrate ADS, pseudosub-
strate ADA and control peptide XX, or de¢ned regions of CK2 sub-
units were synthesized as described previously [18]. Polyclonal anti-
bodies were raised in rabbits against CK2 subunit peptides (anti-K ;
anti-KP ; anti-L), puri¢ed, and characterized as reported elsewhere [18].
Recombinant CK2 subunits were prepared following a standard pro-
cedure established in our laboratory [20].
2.3. Microinjection and indirect immuno£uorescence analysis
Microinjection of IMR-90 cells was performed with an Automated
Injection System (AIS) from Zeiss, essentially as described previously
[15,16]. A Flamming/Brown micropipette puller (Model P-87 from
Sutter Instruments Co.) was used for production of the capillaries.
The settings of the machine were tentatively optimized for e⁄cient
nuclear injections. Immediately after microinjection, the cells were
stimulated to enter the cell cycle (see above), and BrdU was added
to the medium. After 24 h of stimulation, cells were ¢xed by incuba-
tion in prechilled methanol (320‡C) for 10 min, and dipping in ace-
tone, and stored in 70% ethanol for up to 1 week until immuno£uo-
rescence analysis was performed as follows. Cells were rehydrated in
ice-cold phosphate-bu¡ered saline (PBS) and incubated with 5-(4,6-
dichlorotriazinyl)amino £uorescein (DTAF)-labeled anti-rabbit anti-
body (Dianova) allowing detection of ADS-, ADA- or XX-injected
cells by co-injected rabbit preimmune IgG fraction, or cells injected
with CK2 subunit antibodies. After washing twice with PBS, the cells
were kept for 5 min in the presence of 1.5 M HCl, incubated with
antibody against BrdU raised in mice (Boehringer Mannheim),
washed three times with PBS and further incubated with a tetra-
methylrhodamine isothiocyanate (TRITC)-labeled anti-mouse anti-
body (Dianova). Thereafter, the overall DNA was stained with
Hoechst dye 33258 (Serva; ¢nal concentration 1 Wg/ml) and after
two washes with PBS, the coverslip was dipped in water and mounted
in Mowiol 4-88 (Hoechst). In all cases, antibodies were diluted in 3%
BSA and 0.02% Tween-20 in PBS, and allowed to react with cells for
30 min. Washing was carried out by immersing the coverslips in PBS
for 5 min with gentle shaking. Whenever BrdU incorporation into
DNA could be detected (see above), the cells were counted as stim-
ulation positive. The inhibition of cell cycle re-entry was calculated
using the following formula: [BrdU-positive cells (not injected) minus
BrdU-positive cells (injected)]/BrdU-positive cells (not injected). For
the sake of clarity, the calculated value was multiplied by 100, thereby
corresponding to the % of cells whose re-entry into the cell cycle had
been prevented [15,16].
2.4. Miscellaneous
Cell fractionation, SDS-PAGE and Western immunoblotting were
performed as described previously [15,18]. For comparison of a given
protein sequence with databases, the program HUSAR (German Can-
cer Research Center, Heidelberg) based on the GCG program pack-
age version Unix-7.1 (1992, Copyright Genetics Computer Group,
Inc.) was used.
3. Results
3.1. Cellular partition of CK2 subunits K and KP closely
resembles that of L
A⁄nity puri¢ed, monospeci¢c polyclonal antibodies raised
in rabbits against peptides representing the C-terminal region
329^343 of subunit K (peptide K329^343) and the completely
unrelated region 336^350 of subunit KP (peptide KP336^350)
were used in the present study [18]. The antibodies, anti-K329^
343 and anti-KP336^350, showed no cross-reactivity in West-
ern blots with the puri¢ed recombinant K and KP subunits nor
with proteins present in lysates of the investigated IMR-90
¢broblasts, and neither of them recognized subunit L (Fig.
1A). The antibodies were able to precipitate K and KP, respec-
tively, and to co-precipitate L. Western blot detection and
precipitations were e⁄ciently competed by peptide K329^343
and KP336^350, respectively, and neither of the antibodies in-
hibited the phosphorylation reaction of CK2 in vitro [18]. The
antibodies recognized their targets also as they appeared in
the cell, i.e. within their cellular context as opposed to the
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Table 1
E¡ect of microinjected CK2 substrate-related peptides on prolifera-
tion stimulation
Microinjection Inhibition (%)
Nucleus Cytoplasm
ADS 28 þ 8 (5) 35 þ 14 (4)
ADA 53 þ 11 (5) 4 þ 4 (5)
XX 13 þ 9 (7) 0 þ 10 (7)
Quiescent IMR-90 cells were microinjected into the nucleus or the
cytoplasm with peptides RRRADDSDDDDD (ADS, 5 mg/ml),
RRRADDADDDDD (ADA, 5 mg/ml), or DDRDDRDADADR
(XX, 5 mg/ml) prior to proliferation stimulation. Rabbit pre-immune
serum (1.5 mg/ml) was included in injection solutions in order to
visualize microinjected cells by anti-rabbit antibodies. After microin-
jection, cells were stimulated with serum (20% ¢nal concentration)
and incubated in the presence of BrdU. 24 h post-stimulation, cells
were ¢xed and BrdU incorporation visualized by indirect immuno-
£uorescence. Data represent mean values of inhibition of serum stim-
ulation þ S.E.M.; numbers in parentheses indicate the number of
independent experiments (at least 200 microinjected cells each). For
details of calculation see Section 2.
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Western blot situation; immunohistochemical investigations
of IMR-90 cells led to clear-cut immuno£uorescence signals.
For both K and KP, a predominant nuclear location was in-
dicated (Fig. 1B), closely resembling the location of L in pre-
vious investigations [2,14^16]. Essentially the same cellular
partition was obtained by another approach, cell fractionation
followed by Western blot determination of the CK2 subunits.
The levels of K and KP were signi¢cantly higher in the nuclear
than the cytoplasmic fractions of both proliferating and qui-
escent cells, and a higher overall level of K and KP seemed to
exist in proliferating than in quiescent cells, L showing corre-
sponding levels and corresponding nuclear-cytoplasmic parti-
tion (Fig. 1C).
3.2. Nuclear but not cytoplasmic injection of CK2 peptide
substrate and pseudosubstrate interferes with proliferation
stimulation
In order to test more directly whether the phosphotransfer-
ase function of CK2, i.e. the enzymatic activity of K and KP,
has signi¢cance for proliferation stimulation, microinjection
experiments were carried out with a model peptide substrate
and its pseudosubstrate version in which the phosphorylated
Ser was exchanged for Ala. These were expected to compete
for cellular phosphorylations including those necessary for the
serum stimulation to occur, and thus to result in its inhibition.
The model substrate chosen was RRRADDSDDDDD
(ADS), which is among the CK2 peptide substrates with the
lowest Km and the highest Vmax [17], and which is widely used
for the determination of CK2 activity in cell and tissue homo-
genates. The pseudosubstrate corresponding to ADS was pep-
tide RRRADDADDDDD (ADA). IMR-90 cells grown on
coverslips and arrested in the G0 phase were microinjected
with the peptides prior to serum stimulation. Microinjected
cells were visualized via co-injected IgG fraction of rabbit
pre-immune serum that had no e¡ect on stimulation by itself.
As a measure of cell cycle entry, the reaching of S phase
(DNA synthesis) was monitored by the incorporation of a
detectable DNA precursor BrdU, using indirect immuno£uo-
rescence 24 h post-stimulation. As previously shown [16], the
cells require roughly 16 h under the conditions used to reach S
phase. When injected into the nucleus, ADS signi¢cantly in-
hibited the stimulation by serum (Table 1). By contrast, in-
jection into the cytoplasm had little or no e¡ect. Also ADA
was inhibitory upon nuclear injection. The inhibition turned
out to be even considerably stronger, i.e. roughly twice as high
as with ADS. Cytoplasmic ADA injection had, similar to
ADS, little or no e¡ect. As a control, a peptide of the same
length composed of the same amino acids but arranged in a
random order was used, peptide DDRDDRDADADR (XX).
Neither nuclear nor cytoplasmic injection of XX a¡ected pro-
liferation stimulation. Both ADS and ADA, but not XX, in-
hibited the in vitro kinase activity of recombinant catalytic
subunits and reconstituted CK2 holoenzymes (for details of
recombinant CK2 and kinase assay, see [20]). The IC50 values
were calculated to be approximately 0.5^1 mM peptide (data
not shown). On the basis of volumes roughly approximated
for mammalian cells [21] and for the injected solutions [15,22],
the peptide concentrations within nuclei and cytoplasms of
injected cells were calculated to reach a similar order of mag-
nitude. It was concluded that an undisturbed cellular perform-
ance of the phosphotransferase function of K and KP is needed
for the serum stimulation to occur, and, further, that the
phosphorylation reactions catalyzed in the nucleus are of par-
ticular importance.
3.3. Nuclear but not cytoplasmic injection of antibodies against
K and KP interferes with proliferation stimulation of cells
When IMR-90 cells arrested in the G0 phase were micro-
injected with the antibodies anti-K329^343 or anti-KP336^350
prior to serum stimulation, also a signi¢cant proportion of
cells was prevented from cell cycle entry (Table 2). Surpris-
ingly, and in contrast to antibodies against L [15,16], the in-
hibition was restricted to microinjections targeted to the nu-
clear compartment, while no signi¢cant e¡ect was observed
when the antibodies were injected into the cytoplasm. The
e¡ect of both antibodies could essentially be suppressed by
co-injection of peptides K329^343 and KP336^350, respec-
tively. The peptides alone had no e¡ect, supporting the as-
sumption that the interference with proliferation stimulation
by the antibodies was speci¢c for processes mediated by K and
KP. Control injections with pre-immune serum under the same
experimental conditions had no e¡ect. When anti-K329^343
and anti-KP336^350 were injected together, the inhibition did
not exceed the extent obtained with either antibody alone
(Table 2), and, further, remained the same when the antibod-
ies were injected in a more diluted form (roughly at half the
concentrations; data not shown). Thus, the inhibitory action
of the antibodies was obviously not additive but each of them
already gave a maximum. Because the antibodies were not
inhibitory for the phosphorylation of CK2 substrates in vitro
(see above), it was concluded that cellular interactions other
than by phosphorylation mediated by K and KP (non-phos-
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Table 2
E¡ect of microinjected antibodies against CK2 subunits K and KP on proliferation stimulation
Microinjection Inhibition (%)
Nucleus Cytoplasm
Anti-K329^343 36 þ 15 (10) 36 þ 10 (5)
Anti-K329^343+K329^343 10 þ 8 (2) 1 þ 6 (3)
Anti-KP336^350 31 þ 18 (4) 0 þ 13 (39)
Anti-KP336^350+KP336^350 0 þ 9 (4) 2 þ 10 (6)
Anti-K329^343+anti-KP336^350 28 þ 10 (6) 2 þ 6 (5)
Rabbit IgG 0 þ 15 (3) 31 þ 8 (7)
Quiescent human lung ¢broblasts (IMR-90) were microinjected into the nucleus or into the cytoplasm with a⁄nity-puri¢ed antibodies (anti-K329^
343, anti-KP336^350; 2 mg/ml each) in the absence or presence of peptides corresponding to the epitopes recognized by the antibodies (K329^343,
KP336^350; 10 mg/ml each) as indicated. Controls received rabbit preimmune serum (rabbit IgG, 3.2 mg/ml). For further details see legend to Table
1. Data represent mean values þ S.E.M.; numbers in parentheses indicate the number of independent experiments (at least 200 microinjected cells
each).
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phorylation interactions) occur and, particularly in the nu-
cleus, are of importance for the serum-stimulated entry of
cells into the cell cycle, and that these are not speci¢c for
one of the two subunits.
4. Discussion
The inhibition of the proliferation response to serum of
quiescent ¢broblasts by microinjected CK2 peptide substrate
ADS or pseudosubstrate ADA, but not by control peptide
XX (isoform of ADS composed of the same amino acids
but in a random arrangement), is strong, more direct evidence
for a role of CK2-mediated phosphorylation in the process of
serum-stimulated cell cycle entry, since both ADS and ADA,
but not XX, inhibit in vitro the phosphorylation of substrate
proteins by CK2. This provides experimental support for ear-
lier reasoning based on indirect data obtained with microin-
jected anti-L antibodies. Viewing L as a constitutive, phos-
phorylation-determining part of the tetrameric CK2
holoenzymes, the inhibitory e¡ects of anti-L on serum stimu-
lation had been interpreted as being indicative for a require-
ment of phosphorylation by CK2 [15,16,23]. The immuno-
staining and cell fractionation data presented here are in
perfect agreement with this reasoning. The data suggest com-
parable cytoplasmic-nuclear partition of all three of the CK2
subunits ^ K, KP, and L ^ both in quiescent and in proliferat-
ing cells, and, because of the well-known extremely high af-
¢nity of catalytic and regulatory subunits for each other [1^4],
the presence of K2L2, KP2L2, and/or KKPL2 tetramers through-
out cells. However, this view seems oversimpli¢ed. The per-
turbation e¡ects observed with the injected CK2 substrate and
pseudosubstrate peptides do not correlate throughout the cell
with those observed with the injected anti-L antibodies; while
correlating in the nucleus, they seem to deviate in the cyto-
plasm. In addition, there are hints that the participation of
catalytic subunits might include non-phosphorylation interac-
tions separable experimentally from their kinase function.
Cytoplasmic injections of ADS and ADA, unlike cytoplas-
mic injections of anti-L, surprisingly have little e¡ect on serum
stimulation. This seems to question the signi¢cance of the
anticipated cytoplasmic requirement of phosphorylation by
CK2 for serum stimulation and thus for the transport of
signals from plasma membrane into nucleus. This was unex-
pected, since several cytoplasm-located elements of signaling
cascades have been shown to be a¡ected by CK2 phospho-
rylation [1,2,4]. Because ADS has successfully been used as a
speci¢c CK2 substrate allowing for determination of CK2’s
kinase activity (and di¡erentiation from the activity of other
kinases) in crude cell and tissue extracts that hardly contain
less of unspeci¢c targets for ADA than the cytoplasm of ¢-
broblasts, possible unspeci¢c interactions of ADA with other
cellular constituents should not hinder from a detectable in-
hibition also of CK2-mediated phosphorylation and thus of
serum stimulation, as opposed to the zero e¡ect observed. A
zero e¡ect, on the other hand, would be obtained when CK2
phosphorylation was involved in signaling, but was connected
to the negative control, as exempli¢ed for the MAP kinase
pathway by the activation of protein phosphatase 2A due to
its CK2-mediated phosphorylation [24]. In this case, inhibi-
tion of CK2 phosphorylation by the injected peptides would
rather support the maintenance of the pathway. Because con-
tinued activity of the MAP kinase pathway seems to be a
secured feature of serum stimulation of ¢broblasts [12], this
would go unrecognized by the experimental approach em-
ployed. For the sake of clarity, it should be mentioned that
also unrecognized by the employed approach would be in-
volvement of CK2 in other cytoplasmic processes, including
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Fig. 1. Distribution of CK2 subunits in IMR-90 cells. A: Speci¢city
of antibodies for the individual CK2 subunits K and KP. 40 Wg of
cell lysate protein from exponentially growing IMR-90 cells (lane 1),
30 ng each of puri¢ed recombinant K and L subunits of CK2 (lane
2), or 50 ng of puri¢ed recombinant KP subunit of CK2 (lane 3)
were subjected to SDS-PAGE and blotted to PVDF membrane. The
blot was probed with antibodies anti-K329^343 or anti-KP336^350
directed against unrelated sequence sections of K and KP. The posi-
tions of CK2 subunits (K, KP and L) and of molecular mass markers
(kDa) are indicated. B: Intracellular distribution of CK2 subunits
indicated by indirect immuno£uorescence. IMR-90 cells grown on
coverslips were ¢xed with paraformaldehyde, permeabilized with
Triton X-100, incubated with rabbit antibodies against the individu-
al CK2 subunits (anti-K329^343, anti-KP336^350, or anti-L55^70),
stained with a TRITC-conjugated anti-rabbit IgG antibody, and £u-
orescence signals detected with a £uorescence microscope (Zeiss).
Bar represents 10 Wm. C: Intracellular distribution of CK2 subunits
indicated by cell fractionation. Approximately 1.5U106 exponen-
tially proliferating or quiescent IMR-90 cells were homogenized,
separated by centrifugation into a cytoplasmic (C) and a nuclear
(N) fraction, and subjected to SDS-PAGE. Individual CK2 subunits
were detected by Western blotting using a mixture of antibodies
(anti-K329^343, anti-KP336^350, and anti-L55^70). The positions of
molecular mass markers (kDa) and of CK2 subunits (K, KP, and L)
are indicated.
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translation, metabolism, vesicle tra⁄cking, cytoskeletal re-
modeling, etc.
If not based on CK2 phosphorylation, how then to explain
the previously observed inhibition of serum stimulation by
cytoplasmic injections of anti-L [15,16]? An explanation might
come from the pool situation of the CK2 subunits. Certain
pools of subunits may be needed at the receiving end of pro-
liferation-regulating pathways, i.e. in the nucleus. Unlike the
catalytic subunits, L has no obvious nuclear leader sequence
(NLS) and, in addition, seems to be prone to dimerization
[25]. As a consequence, while K and KP might easily trans-
locate into the nucleus, L might not. One might speculate
the L-L complexes to be too large for unrestricted cytoplas-
mic-nuclear translocation (or unsuited for other reasons), and
to depend on an interaction with other protein(s) possessing
NLS. Injected anti-L might inhibit such interaction(s). The
resulting transport inhibition would then hinder proper gen-
eration or maintenance of pool(s) of L in the nucleus and
cause the observed inhibition of serum stimulation. In fact,
the cell fractionation data indicate increased nuclear levels of
CK2 subunits in proliferating cells, and, importantly, the cy-
toplasmic injection of anti-L has been demonstrated to inhibit
both the translocation of L into the nucleus (or of L-contain-
ing molecular complexes recognized by anti-L) and the pro-
liferation stimulation by serum [15,23]. An alternative explan-
ation might be that L could, in addition to the function as a
CK2 regulator, play independent cytoplasmic role(s) linked to
signaling in one way or another. Using L as a bait in yeast-
based two-hybrid systems, a considerable number of cytoplas-
mic proteins have been identi¢ed as potential interaction part-
ners [26^28]. Some of these might turn out to represent signal-
ing proteins that intimately interact with L, but that do not
need phosphorylation by CK2.
Injected into the ¢broblasts’ nuclei, ADS and ADA signi¢-
cantly interfere with serum stimulation, indicating a require-
ment for undisturbed phosphorylation by CK2. Compared to
cytoplasm, the nuclei possess high levels of all three of the
CK2 subunits, as indicated correspondingly by the immunos-
taining and cell fractionation results. Various roles have been
postulated for the nuclear CK2 [1^4]. In the context of the
presented data, those linked to transcription appear to be of
particular concern, because cell cycle entry does not occur
without the expression of genes. Using a cDNA microarray
representing more than 8000 human genes, serum stimulation
of ¢broblasts has been reported to cause diverse temporal
pro¢les of gene expression and repression following an orderly
expression program choreography, and the immediate re-
sponse to be dominated by the expression of genes that en-
code known or suspected regulators of transcription and other
proteins involved in signal transduction, including transcrip-
tion factors Fos, Jun, and Myc [12]. These represent well-
known CK2 substrates [4], and their phosphorylation might
relate to functional control [29,30]. Another such CK2 sub-
strate related to serum stimulation is the serum response fac-
tor (SRF; p67), a MADS family transcription factor [31] with
binding motifs present in the control region of many genes,
including immediate early genes, and with transactivational
roles that appear to be modulated through phosphorylation
by CK2 [32^34]. Thus, both the expression of the genes and
the performance of the gene products as gene regulators may
relate to the phosphorylation by CK2, including, as shown for
the three AP1 binding proteins ^ Fos, Jun, Nrf1 ^ the balanc-
ing of the action of transcriptionally active proteins [35]. Most
of these phosphorylations, however, appear to be catalyzed by
CK2 holoenzymes and thus are under the control of subunit L
[20]. This is in perfect agreement with the dramatic inhibition
obtained previously by nuclear injections of anti-L antibodies
[15,16]. Inhibition has been obtained only when injected with-
in the ¢rst several hours after serum application, i.e. during
G0/G1 phase transition and the early part of the G1 phase,
and, moreover, has been shown to be accompanied by expres-
sion inhibition of immediate early genes such as fos [36]. In
addition, L-mediated non-phosphorylation interactions might
have been a¡ected by anti-L injections such as known to occur
with p53 [37], increasing the inhibitory e¡ect.
We show here that non-phosphorylation interactions may
not only occur via L. Non-phosphorylation interactions ap-
pear to occur also at the catalytic subunits of CK2 that can
experimentally be separated from their phosphorylation func-
tion. This is re£ected by the inhibition of serum stimulation
due to nuclear injections of the antibodies anti-K329^343 and
anti-KP336^350. These had been raised and are speci¢cally
directed against unique sequences downstream of the catalytic
domain regions, ¢nd their targets under conditions of Western
blotting, immunohistochemistry, and immunoprecipitations
[18], are competitively inhibited by the peptides used as anti-
gens, and, consequently, a¡ect neither the complexation of K
and KP to L, i.e. proper holoenzyme formation, nor the in
vitro kinase activity of holoenzymes or of the individual cata-
lytic subunits [18,19]. Because it is the same in extent with
both antibodies and not additive in their e¡ects, the inhibition
of serum stimulation should relate to features inherent in both
K and KP, i.e. to features speci¢c for catalytic subunits gener-
ally. Another such feature(s) appears to exist upstream of
kinase domain areas at position 15^27 of K (KP position 16^
28; three mismatches to K), because nuclear injection of anti-
K15^27, an antibody directed against both K and KP, also
inhibits serum stimulation to a comparable extent (data not
shown). At present, the meaning and abundance of these non-
phosphorylation interactions of the catalytic subunits is not
clear. The bound antibodies might prevent interactions that
occur in addition to phosphorylation, or interactions that fa-
cilitate phosphorylation, or both. Facilitating phosphorylation
could be via anchoring of CK2 to speci¢c nuclear substrates
that may otherwise not become CK2 substrates. A related
example would be the anchoring of the c-Jun N-terminal kin-
ase (JNK) to the delta region of c-Jun, a region physically
distinct from the phosphoacceptor region within its activation
domain, that facilitates phosphoacceptor region translocation
into the catalytic cleft of JNK leading to phosphorylation and
subsequent dissociation of the kinase from its substrate [38]. If
this was the case, the non-phosphorylation interaction would
be part of the phosphorylation process. However, although
seemingly obvious, currently we have neither data that would
substantiate this idea, nor can we exclude CK2 interactions
that are related to serum stimulation but concern cellular
constituents other than CK2 substrates and thus occur in
addition to phosphorylation.
The non-phosphorylation interaction(s) even by the cata-
lytic subunits add one more feature to the already complex
cellular scenario with CK2. Obviously, viewing CK2 as a
housekeeping enzyme that functions exclusively as phospho-
transferase and in a tetrameric form throughout the cell is
inadequate. The presented data rather strengthen the view
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of an occurrence of various pools with speci¢c cellular loca-
tions and functions, pools that contain not only holoenzymes.
The existence of such pools has been considered previously
[39,40]. Their formation and maintenance may rely on an-
choring proteins [41] similar to those known for other protein
kinases such as PKC and PKA (Racks and AKAPs, respec-
tively; reviewed in [42]). The lining of structures such as mi-
crotubules or the presence of discrete dots at places observed
with antibody staining [2,43,44] might be indications. In addi-
tion to holoenzymes, the individual subunits might form pools
([39,45], our unpublished data), a problem that is receiving
more and more attention. The deviations from the tetrameric
stoichiometry appear to have relevance particularly for patho-
logical situations. A most dramatic example is that of T cells
transformed by the parasite Theileria parva resulting in a leu-
kemia-like deadly disease of cattle, characterized by what
seems to be a causal link to extremely high levels of individual
K [8]. In transgenic mice, moderate overexpression of K has
been shown to result in a stochastic propensity to lymphoma
development giving rise to a high incidence of lymphoproli-
ferative disease upon mating K transgenic mice with c-myc or
tal-1 transgenic mice [9,10], or with p53 knockout mice [11].
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